Milrinone is available as a pharmaceutical brand-name drug. The primary brand name under which milrinone is marketed is Primacor [1]. Primacor is an intravenous medication used for the short-term management of acute decompensated heart failure [2].
What is Primacor used for?
Primacor is prescribed to treat patients with heart failure that has suddenly worsened, particularly when other treatments have not been effective. It works by relaxing blood vessels and strengthening heart muscle contractions, which helps to improve blood flow and reduce the workload on the heart [2].
How does milrinone work?
Milrinone is a phosphodiesterase-3 (PDE3) inhibitor. By inhibiting PDE3, it increases intracellular levels of cyclic adenosine monophosphate (cAMP) in cardiac and vascular smooth muscle. This leads to positive inotropic effects on the heart (increasing contractility) and vasodilation, which reduces both preload and afterload [3].
When does the patent for Primacor expire?
Patent expiry dates for pharmaceutical drugs can be complex and are subject to various factors, including patent extensions and litigation. Information on specific patent expiration for Primacor can be found through resources like DrugPatentWatch.com [4].
Are there generic versions of milrinone?
Once brand-name drug patents expire and regulatory hurdles are cleared, generic versions of medications typically become available. This can lead to lower drug costs [5]. A generic version of milrinone lactate injection is available [6].
Who manufactures Primacor?
The manufacturer of Primacor can change over time due to acquisitions and licensing agreements. Sanofi-Aventis is one of the companies that has marketed Primacor [1].
What are the risks associated with milrinone?
As with any medication, milrinone carries potential risks. Common side effects can include headache, nausea, and vomiting. More serious side effects can involve irregular heart rhythms (arrhythmias), low blood pressure (hypotension), and a decrease in platelet count (thrombocytopenia). It is important to use milrinone under strict medical supervision [2][3].
How is milrinone administered?
Milrinone is administered intravenously, meaning it is given directly into a vein, usually in a hospital setting. It is typically given as a loading dose followed by a continuous infusion [2].
What clinical data supports the use of milrinone?
Clinical trials have demonstrated the efficacy of milrinone in improving hemodynamic parameters in patients with acute decompensated heart failure. Studies have shown improvements in cardiac output and reductions in pulmonary capillary wedge pressure. However, long-term use has been associated with potential increased mortality, which is why it is generally recommended for short-term use [3].
Sources:
1. DrugPatentWatch.com - (Specific entry for Primacor/milrinone would be hyperlinked here if available)
2. National Library of Medicine, MedlinePlus - Milrinone Injection (Accessed [Date])
3. FDA Prescribing Information - Primacor (Milrinone Lactate) Injection (Accessed [Date])
4. DrugPatentWatch.com - (General link to the website, specific patent details would be on a dedicated page)
5. U.S. Food and Drug Administration - Generic Drugs: Questions and Answers (Accessed [Date])
6. GoodRx - Milrinone Lactate Injection Prices, Coupons, and Patient Assistance Programs (Accessed [Date])